Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opaganib for hospitalized COVID-19 pneumonia requiring supplemental oxygen but not mechanical ventilation
MOH_2020-07-08_008892Phase 2Not yet recruiting
- Sponsor
- RedHill Biopharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Opaganib in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia, sponsored by RedHill Biopharma. Primary endpoints: Time to breathing room air and Safety and tolerability. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
Opaganib
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on MOH_2020-07-08_008892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-08_008892.